Management and Prevention of Paramyxoviruses in Hematopoietic Cell Transplantation Recipients

This session will cover the latest guidelines for managing respiratory syncytial virus (RSV) and other paramyxoviruses, focusing on epidemiology, clinical diagnosis, prophylaxis, and treatment strategies. Experts will discuss special considerations for pediatric, cord blood, haploidentical, and T cell-depleted HCT patients, as well as chimeric antigen receptor T cell therapy recipients. Review the recently published guidelines here.

Learning Objectives:

• Analyze the epidemiological patterns and risk factors of paramyxovirus infections in hematopoietic cell transplantation (HCT) recipients.
• Evaluate and differentiate the key clinical features for diagnosing respiratory syncytiavirus (RSV) and other paramyxovirus infections in HCT patients.
• Apply current prophylaxis and treatment strategies for paramyxovirus infections in HCT recipients, comparing their effectiveness and potential outcomes.
• Synthesize special considerations for paramyxovirus management in specific HCT patient populations, integrating various factors that influence treatment decisions

Panelists:

• Marjorie Vieira Batista, MD ACCamargo Cancer Center
• Alpana Waghmare, MD Department of Pediatrics, University of Washington School of Medicine

Moderators:

• Roy Chemaly, MD Department of Infectious Diseases, MD Anderson Cancer Center
• Diego R Hijano, MD, MSc St. Jude Children's Research